4884.T
Kringle Pharma,Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 559.00
−3.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 72.0M | 72.0M | 80.0M | 69.0M | 391.0M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 18.6M | 72.2M | 80.0M | 69.3M | 303.4M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 218.5M | 981.7M | 897.9M | 958.0M | 729.6M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 218.5M | 981.7M | 897.9M | 958.0M | 729.6M |
| Cost and Expenses | 968.0M | 981.0M | 897.0M | 957.0M | 817.0M |
| Operating Income (EBIT) | (896.0M) | (909.0M) | (817.0M) | (888.0M) | (426.0M) |
| Non-Operating | |||||
| Interest Income | — | 67.0K | 10.0K | 5.0K | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (142.0K) | (5.3M) | — | 36.1M | 95.8M |
| Non-Operating Income (excl Interest) | — | 1.5M | 62.9M | 43.4M | 104.2M |
| EBT (Pre-Tax Income) | (201.5M) | (914.8M) | (755.0M) | (852.7M) | (330.3M) |
| Income Tax Expense | 372.0K | 1.5M | 1.5M | 1.5M | 1.5M |
| Bottom Line | |||||
| Net Income | (905.0M) | (916.0M) | (756.0M) | (854.0M) | (331.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (905.0M) | (916.0M) | (756.0M) | (854.0M) | (331.0M) |
| Per Share | |||||
| Basic EPS | (¥131) | (¥134) | (¥118) | (¥158) | (¥68) |
| Diluted EPS | (¥131) | — | — | — | — |
| Revenue Per Share | ¥10 | ¥11 | ¥13 | ¥13 | ¥81 |
| Shares | |||||
| Basic Shares Outstanding | 7.2M | 6.8M | 6.4M | 5.4M | 4.9M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | — | — | — |
| D&A | — | — | — | — | — |
| EBIT | (896.0M) | (909.0M) | (817.0M) | (888.0M) | (426.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026